Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with R-HyperCVAD/R-MA in Untreated Mantle Cell Lymphoma
NCT00477412Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2007
- Primary completion
- Oct 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00477412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00477412.